Takeda ditches late-stage Ninlaro trial
The company remains "optimistic about Ninlaro and continue to investigate Ninlaro in patient populations across the continuum of multiple myeloma care".
6th June 2019
Latest news
New NHS innovations to benefit 750,000
The innovations include a new pre-eclampsia test for pregnant women and an advanced blood test for heart attack diagnosis.
6th June 2019
Sales Awards finalists give their thoughts on the competition
The prestigious PharmaTimes Sales Awards has been recognised by finalists and winners on its highly beneficial and rewarding challenges.
6th June 2019
Death risk from sepsis lasts up to five years
The research, published in JAMA Network Open today, found that 15% of sepsis survivors died within a year of leaving hospital.
5th June 2019
AbbVie, Roche present positive Venclyxto results at ASCO
Venclyxto is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 protein.
5th June 2019
Lynparza ASCO success continues with positive ovarian cancer results
The treatment achieved a 72% objective response rate in patients with previously treated germline BRCA1/2-mutated advanced ovarian cancer.
5th June 2019
FDA ‘yes’ for Emgality in cluster headache
In a trial, patients taking Emgality experienced 8.7 fewer weekly cluster headache attacks than they did at baseline.
5th June 2019
Categories available for all experience levels in the 2019 Marketer of the Year competition
There are a broad range of categories in the PharmaTimes Marketer of the Year competition, designed to cover all sectors and suitable for all experience levels.
4th June 2019
New late stage prostate cancer technology available in UK
The technology, called Theranostics, provides a personalised approach to treatment and diagnosis in prostate cancer.
4th June 2019
Bluebird bags EU conditional marketing authorisation for Zynteglo
The authorisation for the inherited blood disorder marks bluebird’s first ever drug approval.
4th June 2019
Thousands more GP staff recruited across England
The recruitment drive means that there are now 7,302 more full time equivalent health professionals working in primary care.
4th June 2019
Promising early results for BMS’ investigational HCC study
The company are "encouraged by these early results", as liver cancer affects over 5,700 new patients in the UK each year.
4th June 2019
Janssen presents positive Darzalex results at ASCO
The drug showed non-inferior efficacy and a significantly higher complete response rate in two different trials.
3rd June 2019
Novartis’ Kisqali hits endpoints in Phase III breast cancer trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.
3rd June 2019
‘Unprecedented’ results in AZ’ late-stage Lynparza trial
The results were announced at the 2019 ASCO meeting.
3rd June 2019
